Vir Biotechnology (VIR) Assets Average (2019 - 2026)

Vir Biotechnology (VIR) has 8 years of Assets Average data on file, last reported at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 25.06% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (down 25.06% YoY), and the FY2025 full-year result was $1.2 billion, down 27.62% from the prior year.
• Assets Average steadied at $1.0 billion in Q1 2026, from $1.0 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $2.8 billion in Q2 2022 to a low of $1.0 billion in Q4 2025.
• A 5-year average of $1.9 billion and a median of $1.9 billion in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average jumped 151.06% in 2022 and tumbled 32.1% in 2024, its largest moves.
• Tracing VIR's Assets Average over 5 years: stood at $2.7 billion in 2022, then retreated by 27.9% to $2.0 billion in 2023, then slipped by 26.91% to $1.4 billion in 2024, then slumped by 30.2% to $1.0 billion in 2025, then rose by 0.3% to $1.0 billion in 2026.
• Business Quant data shows VIR's Assets Average at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.1 billion in Q3 2025.